These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26659791)

  • 21. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus.
    Almquist J; Kuruvilla D; Mai T; Tummala R; White WI; Tang W; Roskos L; Chia YL
    J Clin Pharmacol; 2022 Sep; 62(9):1106-1120. PubMed ID: 35383948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
    Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.
    Yu T; Enioutina EY; Brunner HI; Vinks AA; Sherwin CM
    Clin Pharmacokinet; 2017 Feb; 56(2):107-125. PubMed ID: 27384528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.
    Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P
    Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.
    Higgs BW; Zhu W; Morehouse C; White WI; Brohawn P; Guo X; Rebelatto M; Le C; Amato A; Fiorentino D; Greenberg SA; Drappa J; Richman L; Greth W; Jallal B; Yao Y
    Ann Rheum Dis; 2014 Jan; 73(1):256-62. PubMed ID: 23434567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.
    Yan L; Wang B; Chia YL; Roskos LK
    Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.